FI3250592T3 - Transtyretiinin vastaisia vasta-aineita - Google Patents
Transtyretiinin vastaisia vasta-aineita Download PDFInfo
- Publication number
- FI3250592T3 FI3250592T3 FIEP16702812.5T FI16702812T FI3250592T3 FI 3250592 T3 FI3250592 T3 FI 3250592T3 FI 16702812 T FI16702812 T FI 16702812T FI 3250592 T3 FI3250592 T3 FI 3250592T3
- Authority
- FI
- Finland
- Prior art keywords
- heavy chain
- antibody
- seq
- mature
- antibody according
- Prior art date
Links
- 150000007523 nucleic acids Chemical class 0.000 claims 5
- 102000039446 nucleic acids Human genes 0.000 claims 5
- 108020004707 nucleic acids Proteins 0.000 claims 5
- 108010071690 Prealbumin Proteins 0.000 claims 4
- 102000009190 Transthyretin Human genes 0.000 claims 4
- 239000013604 expression vector Substances 0.000 claims 4
- 238000003259 recombinant expression Methods 0.000 claims 4
- 206010002022 amyloidosis Diseases 0.000 claims 3
- 210000004027 cell Anatomy 0.000 claims 3
- 239000012634 fragment Substances 0.000 claims 3
- 230000001404 mediated effect Effects 0.000 claims 3
- 238000000034 method Methods 0.000 claims 3
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims 2
- 239000004472 Lysine Substances 0.000 claims 2
- 239000012472 biological sample Substances 0.000 claims 2
- 210000004899 c-terminal region Anatomy 0.000 claims 2
- 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 claims 2
- 239000007787 solid Substances 0.000 claims 2
- 102000009490 IgG Receptors Human genes 0.000 claims 1
- 108010073807 IgG Receptors Proteins 0.000 claims 1
- 210000003403 autonomic nervous system Anatomy 0.000 claims 1
- 239000008280 blood Substances 0.000 claims 1
- 210000004369 blood Anatomy 0.000 claims 1
- 239000006143 cell culture medium Substances 0.000 claims 1
- 239000013068 control sample Substances 0.000 claims 1
- 238000012258 culturing Methods 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 210000001035 gastrointestinal tract Anatomy 0.000 claims 1
- 210000002216 heart Anatomy 0.000 claims 1
- 238000000338 in vitro Methods 0.000 claims 1
- 210000003734 kidney Anatomy 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 210000001428 peripheral nervous system Anatomy 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 210000002381 plasma Anatomy 0.000 claims 1
- 210000002966 serum Anatomy 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
- C07K2317/41—Glycosylation, sialylation, or fucosylation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/567—Framework region [FR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biochemistry (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Biomedical Technology (AREA)
- General Chemical & Material Sciences (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- Psychiatry (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pain & Pain Management (AREA)
- Hospice & Palliative Care (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562109002P | 2015-01-28 | 2015-01-28 | |
| US201562266556P | 2015-12-11 | 2015-12-11 | |
| PCT/IB2016/050415 WO2016120810A1 (en) | 2015-01-28 | 2016-01-28 | Anti-transthyretin antibodies |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| FI3250592T3 true FI3250592T3 (fi) | 2023-01-13 |
Family
ID=55299694
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| FIEP16702812.5T FI3250592T3 (fi) | 2015-01-28 | 2016-01-28 | Transtyretiinin vastaisia vasta-aineita |
Country Status (31)
| Country | Link |
|---|---|
| US (1) | US20160251418A1 (enExample) |
| EP (2) | EP3250592B1 (enExample) |
| JP (2) | JP6748086B2 (enExample) |
| KR (2) | KR102677203B1 (enExample) |
| CN (1) | CN107406499B (enExample) |
| AU (1) | AU2016210888C1 (enExample) |
| CA (1) | CA2974912A1 (enExample) |
| CL (2) | CL2017001924A1 (enExample) |
| CO (1) | CO2017008476A2 (enExample) |
| CU (1) | CU24480B1 (enExample) |
| DK (1) | DK3250592T3 (enExample) |
| EA (1) | EA036080B1 (enExample) |
| ES (1) | ES2934656T3 (enExample) |
| FI (1) | FI3250592T3 (enExample) |
| HR (1) | HRP20221538T1 (enExample) |
| HU (1) | HUE060878T2 (enExample) |
| IL (1) | IL253633B (enExample) |
| LT (1) | LT3250592T (enExample) |
| MX (1) | MX394170B (enExample) |
| PE (1) | PE20180217A1 (enExample) |
| PH (1) | PH12017501318A1 (enExample) |
| PL (1) | PL3250592T3 (enExample) |
| PT (1) | PT3250592T (enExample) |
| RS (1) | RS63906B1 (enExample) |
| SA (1) | SA517382002B1 (enExample) |
| SG (2) | SG10202101763VA (enExample) |
| SI (1) | SI3250592T1 (enExample) |
| TW (2) | TWI786505B (enExample) |
| UA (1) | UA122142C2 (enExample) |
| WO (1) | WO2016120810A1 (enExample) |
| ZA (1) | ZA201705663B (enExample) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10464999B2 (en) | 2015-01-28 | 2019-11-05 | Prothena Biosciences Limited | Anti-transthyretin antibodies |
| US9879080B2 (en) | 2015-01-28 | 2018-01-30 | Prothena Biosciences Limited | Anti-transthyretin antibodies |
| US10633433B2 (en) | 2015-01-28 | 2020-04-28 | Prothena Biosciences Limited | Anti-transthyretin antibodies |
| WO2018007922A2 (en) * | 2016-07-02 | 2018-01-11 | Prothena Biosciences Limited | Anti-transthyretin antibodies |
| MX2020003041A (es) | 2017-10-06 | 2020-10-05 | Prothena Biosciences Ltd | Anticuerpos anti-transtiretina. |
| PE20210042A1 (es) | 2017-10-06 | 2021-01-08 | Prothena Biosciences Ltd | Metodos para detectar transtiretina |
| CU20200042A7 (es) | 2017-11-29 | 2021-03-11 | Prothena Biosciences Ltd | Formulación liofilizada de un anticuerpo monoclonal contra la transtirretina |
| CA3118618A1 (en) | 2018-11-09 | 2020-05-14 | Neurimmune Ag | Patient-derived amyloid xenograft non-human animal model |
| JP7728788B2 (ja) | 2020-03-18 | 2025-08-25 | アーエルエス ファルマ アクチェン ゲゼルシャフト | ミスフォールドｓｏｄ１アッセイ |
| WO2021228987A1 (en) | 2020-05-12 | 2021-11-18 | Neurimmune Ag | Combination therapy for ttr amyloidosis |
| US20230340089A1 (en) * | 2020-05-14 | 2023-10-26 | City Of Hope | Smc1a antibodies and uses thereof |
| US20230391859A1 (en) * | 2020-10-28 | 2023-12-07 | Novo Nordisk A/S | Anti-transthyretin antibodies and methods of use thereof |
| CN113845593B (zh) * | 2021-10-27 | 2023-03-10 | 福州迈新生物技术开发有限公司 | 抗α-SMA蛋白单克隆抗体、细胞系及其应用 |
| US20250019425A1 (en) * | 2021-11-12 | 2025-01-16 | Adrx, Inc. | Transthyretin (ttr) monomer binding antibodies |
| CA3239708A1 (en) | 2021-12-03 | 2023-06-08 | Aubin MICHALON | Novel potency assay for antibody-based drugs and useful means therefor |
| US20240228637A9 (en) * | 2022-10-19 | 2024-07-11 | Ibio, Inc. | Chemokine receptor 8 (ccr8) antibodies |
| JP2025537802A (ja) | 2022-11-15 | 2025-11-20 | ニューリミューン アーゲー | トランスサイレチン媒介アミロイドーシスを治療又は予防する方法 |
| WO2024197157A1 (en) * | 2023-03-21 | 2024-09-26 | Biograph 55, Inc. | Cd19/cd38 multispecific antibodies |
| WO2024240562A1 (en) | 2023-05-19 | 2024-11-28 | Neurimmune Ag | Novel immunotherapy for musculoskeletal disorders and conditions |
| TW202528347A (zh) | 2023-11-15 | 2025-07-16 | 瑞士商紐立慕公司 | 抗運甲狀腺素蛋白抗體、包含所述抗體之組成物及用於治療或預防運甲狀腺素蛋白介導之澱粉樣變性的方法 |
| WO2025125544A1 (en) | 2023-12-15 | 2025-06-19 | Novo Nordisk A/S | Stable liquid formulations |
| WO2025238147A1 (en) | 2024-05-15 | 2025-11-20 | Neurimmune Ag | Maintenance treatment of cardiac ttr amyloidosis using anti-transthyretin antibodies |
Family Cites Families (53)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CH652145A5 (de) | 1982-01-22 | 1985-10-31 | Sandoz Ag | Verfahren zur in vitro-herstellung von hybridomen welche humane monoklonale antikoerper erzeugen. |
| US4634666A (en) | 1984-01-06 | 1987-01-06 | The Board Of Trustees Of The Leland Stanford Junior University | Human-murine hybridoma fusion partner |
| US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| EP0832981A1 (en) | 1987-02-17 | 1998-04-01 | Pharming B.V. | DNA sequences to target proteins to the mammary gland for efficient secretion |
| DE3883899T3 (de) | 1987-03-18 | 1999-04-22 | Sb2, Inc., Danville, Calif. | Geänderte antikörper. |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| US5633076A (en) | 1989-12-01 | 1997-05-27 | Pharming Bv | Method of producing a transgenic bovine or transgenic bovine embryo |
| US5859205A (en) | 1989-12-21 | 1999-01-12 | Celltech Limited | Humanised antibodies |
| CA2050918A1 (en) | 1990-01-12 | 1991-07-13 | Raju Kucherlapati | Generation of xenogeneic antibodies |
| US5427908A (en) | 1990-05-01 | 1995-06-27 | Affymax Technologies N.V. | Recombinant library screening methods |
| GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
| WO1992020791A1 (en) | 1990-07-10 | 1992-11-26 | Cambridge Antibody Technology Limited | Methods for producing members of specific binding pairs |
| US5661016A (en) | 1990-08-29 | 1997-08-26 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
| US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
| US5633425A (en) | 1990-08-29 | 1997-05-27 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| US5874299A (en) | 1990-08-29 | 1999-02-23 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| US5770429A (en) | 1990-08-29 | 1998-06-23 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| US5625126A (en) | 1990-08-29 | 1997-04-29 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
| US5877397A (en) | 1990-08-29 | 1999-03-02 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
| US5789650A (en) | 1990-08-29 | 1998-08-04 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
| US5814318A (en) | 1990-08-29 | 1998-09-29 | Genpharm International Inc. | Transgenic non-human animals for producing heterologous antibodies |
| DE69133476T2 (de) | 1990-08-29 | 2006-01-05 | GenPharm International, Inc., Palo Alto | Transgene Mäuse fähig zur Produktion heterologer Antikörper |
| US5871907A (en) | 1991-05-15 | 1999-02-16 | Medical Research Council | Methods for producing members of specific binding pairs |
| US5858657A (en) | 1992-05-15 | 1999-01-12 | Medical Research Council | Methods for producing members of specific binding pairs |
| AU675916B2 (en) | 1991-06-14 | 1997-02-27 | Genentech Inc. | Method for making humanized antibodies |
| US5565332A (en) | 1991-09-23 | 1996-10-15 | Medical Research Council | Production of chimeric antibodies - a combinatorial approach |
| JPH07503132A (ja) | 1991-12-17 | 1995-04-06 | ジェンファーム インターナショナル，インコーポレイティド | 異種抗体を産生することができるトランスジェニック非ヒト動物 |
| US5733743A (en) | 1992-03-24 | 1998-03-31 | Cambridge Antibody Technology Limited | Methods for producing members of specific binding pairs |
| DE69329974T2 (de) | 1992-12-04 | 2001-07-19 | Medical Research Council, London | Multivalente und multispezifische bindungsproteine, deren herstellung und verwendung |
| US5827690A (en) | 1993-12-20 | 1998-10-27 | Genzyme Transgenics Corporatiion | Transgenic production of antibodies in milk |
| US5877218A (en) | 1994-01-10 | 1999-03-02 | Teva Pharmaceutical Industries, Ltd. | Compositions containing and methods of using 1-aminoindan and derivatives thereof and process for preparing optically active 1-aminoindan derivatives |
| US5786464C1 (en) | 1994-09-19 | 2012-04-24 | Gen Hospital Corp | Overexpression of mammalian and viral proteins |
| DE19539493A1 (de) | 1995-10-24 | 1997-04-30 | Thomae Gmbh Dr K | Starker homologer Promotor aus Hamster |
| US5834597A (en) | 1996-05-20 | 1998-11-10 | Protein Design Labs, Inc. | Mutated nonactivating IgG2 domains and anti CD3 antibodies incorporating the same |
| US6114148C1 (en) | 1996-09-20 | 2012-05-01 | Gen Hospital Corp | High level expression of proteins |
| US5888809A (en) | 1997-05-01 | 1999-03-30 | Icos Corporation | Hamster EF-1α transcriptional regulatory DNA |
| ATE490518T1 (de) | 1999-02-05 | 2010-12-15 | Samsung Electronics Co Ltd | Verfahren und vorrichtung zum wiederauffinden von texturbildern |
| TWI255272B (en) | 2000-12-06 | 2006-05-21 | Guriq Basi | Humanized antibodies that recognize beta amyloid peptide |
| EP2298809A3 (en) | 2001-07-12 | 2012-02-15 | FOOTE, Jefferson | Super humanized antibodies |
| ES2289174T3 (es) | 2001-12-28 | 2008-02-01 | Amgen Fremont Inc. | Anticuerpos contra el antigeno muc-18. |
| DE50308030D1 (de) | 2002-11-29 | 2007-10-04 | Boehringer Ingelheim Pharma | Neue neomycin-phosphotransferase-gene und verfahren zur selektion von hochproduzierenden rekombinanten zellen |
| DE10338531A1 (de) | 2003-08-19 | 2005-04-07 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Verfahren zur Reklonierung von Produktionszellen |
| PT1820022E (pt) | 2004-11-10 | 2009-08-05 | Boehringer Ingelheim Pharma | Utilização de análise por citometria de fluxo para optimizar estratégias de conservação de bancos de células cho |
| EP2808020A1 (en) | 2006-04-21 | 2014-12-03 | The Government Of The United States, As Represented by The Secretary Of Health And Human Services | Beta-Amyloid Pet Imaging Agents |
| US20080124760A1 (en) | 2006-07-26 | 2008-05-29 | Barbara Enenkel | Regulatory Nucleic Acid Elements |
| ES2523915T5 (es) | 2006-12-01 | 2022-05-26 | Seagen Inc | Agentes de unión a la diana variantes y usos de los mismos |
| DK2126093T3 (da) | 2007-03-02 | 2013-01-07 | Boehringer Ingelheim Pharma | Forbedring af proteinfremstilling |
| EP2031064A1 (de) | 2007-08-29 | 2009-03-04 | Boehringer Ingelheim Pharma GmbH & Co. KG | Verfahren zur Steigerung von Proteintitern |
| FI20115165A0 (fi) * | 2011-02-21 | 2011-02-21 | Polysackaridforskning I Uppsala Ab | Terapeuttisia ja diagnostisia menetelmiä |
| US9534048B2 (en) * | 2012-08-24 | 2017-01-03 | University Health Network | Antibodies to TTR and methods of use |
| JP2016514091A (ja) * | 2013-02-08 | 2016-05-19 | ミスフォールディング ダイアグノスティクス， インコーポレイテッド | トランスサイレチン抗体およびその使用 |
| US20160168235A1 (en) * | 2013-07-19 | 2016-06-16 | Board Of Regents Of The University Of Texas System | Transthyretin amyloid-selective and polyreactive catabodies |
| PE20210042A1 (es) | 2017-10-06 | 2021-01-08 | Prothena Biosciences Ltd | Metodos para detectar transtiretina |
-
2016
- 2016-01-27 TW TW110100085A patent/TWI786505B/zh active
- 2016-01-27 TW TW105102535A patent/TWI718122B/zh active
- 2016-01-28 SI SI201631652T patent/SI3250592T1/sl unknown
- 2016-01-28 RS RS20221170A patent/RS63906B1/sr unknown
- 2016-01-28 CN CN201680010882.7A patent/CN107406499B/zh active Active
- 2016-01-28 UA UAA201708667A patent/UA122142C2/uk unknown
- 2016-01-28 MX MX2017009806A patent/MX394170B/es unknown
- 2016-01-28 LT LTEPPCT/IB2016/050415T patent/LT3250592T/lt unknown
- 2016-01-28 JP JP2017539650A patent/JP6748086B2/ja active Active
- 2016-01-28 WO PCT/IB2016/050415 patent/WO2016120810A1/en not_active Ceased
- 2016-01-28 US US15/009,662 patent/US20160251418A1/en not_active Abandoned
- 2016-01-28 KR KR1020237037602A patent/KR102677203B1/ko active Active
- 2016-01-28 PT PT167028125T patent/PT3250592T/pt unknown
- 2016-01-28 EA EA201791712A patent/EA036080B1/ru unknown
- 2016-01-28 HU HUE16702812A patent/HUE060878T2/hu unknown
- 2016-01-28 HR HRP20221538TT patent/HRP20221538T1/hr unknown
- 2016-01-28 CU CU2017000097A patent/CU24480B1/es unknown
- 2016-01-28 FI FIEP16702812.5T patent/FI3250592T3/fi active
- 2016-01-28 EP EP16702812.5A patent/EP3250592B1/en active Active
- 2016-01-28 CA CA2974912A patent/CA2974912A1/en active Pending
- 2016-01-28 KR KR1020177023749A patent/KR102598180B1/ko active Active
- 2016-01-28 SG SG10202101763VA patent/SG10202101763VA/en unknown
- 2016-01-28 SG SG11201706124VA patent/SG11201706124VA/en unknown
- 2016-01-28 PE PE2017001287A patent/PE20180217A1/es unknown
- 2016-01-28 AU AU2016210888A patent/AU2016210888C1/en active Active
- 2016-01-28 PL PL16702812.5T patent/PL3250592T3/pl unknown
- 2016-01-28 DK DK16702812.5T patent/DK3250592T3/da active
- 2016-01-28 ES ES16702812T patent/ES2934656T3/es active Active
- 2016-01-28 EP EP22195219.5A patent/EP4134379A1/en active Pending
-
2017
- 2017-07-20 PH PH12017501318A patent/PH12017501318A1/en unknown
- 2017-07-24 IL IL253633A patent/IL253633B/en active IP Right Grant
- 2017-07-27 CL CL2017001924A patent/CL2017001924A1/es unknown
- 2017-07-27 SA SA517382002A patent/SA517382002B1/ar unknown
- 2017-08-21 ZA ZA2017/05663A patent/ZA201705663B/en unknown
- 2017-08-22 CO CONC2017/0008476A patent/CO2017008476A2/es unknown
-
2020
- 2020-08-06 JP JP2020133642A patent/JP7028923B2/ja active Active
-
2022
- 2022-11-02 CL CL2022003027A patent/CL2022003027A1/es unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| FI3250592T3 (fi) | Transtyretiinin vastaisia vasta-aineita | |
| JP2022177090A5 (enExample) | ||
| HRP20220918T1 (hr) | Anti-transtiretinska antitijela | |
| CN105384825B (zh) | 一种基于单域抗体的双特异性嵌合抗原受体及其应用 | |
| RU2012156938A (ru) | Антитела против gdf8 человека | |
| RU2018106364A (ru) | Антитела против рецептора tfr и их применение при лечении пролиферативных и воспалительных расстройств | |
| WO2018036473A1 (zh) | 抗ctla4-抗pd-1双功能抗体、其药物组合物及其用途 | |
| JP2018527919A5 (enExample) | ||
| FI3378535T3 (fi) | Alfa-synukleiinin tunnistavia humanisoituja vasta-aineita | |
| JP2014518615A5 (enExample) | ||
| RU2012137498A (ru) | Фармацевтическая композиция для лечения и/или профилактики рака | |
| NZ610734A (en) | Human antibodies to the glucagon receptor | |
| JP2016505635A5 (enExample) | ||
| RU2013141077A (ru) | Антигенсвязывающие белки | |
| RU2012127380A (ru) | Гуманизированные антитела против il-10 для лечения системной красной волчанки (slt) | |
| JP2019520034A5 (enExample) | ||
| RU2016107814A (ru) | Новое антитело к tslp-рецептору человека | |
| CN113056283A (zh) | 关于治疗血液肿瘤的工程化和非工程化γδ-T细胞的组合物和方法 | |
| MY206214A (en) | Monoclonal antibodies that bind specifically to human trbv9 | |
| CN113173991B (zh) | 一种抗bcma的抗体及其应用 | |
| CN109153720B (zh) | 使用CLEVER-1、TNF-α和HLA-DR结合剂的免疫活化的诊断 | |
| CN111363040A (zh) | 抗ox40的单克隆抗体及其应用 | |
| RU2014117952A (ru) | Антитела против sema4a человека, используемые для лечения заболевания | |
| JP2012523221A5 (enExample) | ||
| AU2022280586B2 (en) | Chimeric antigen receptor specifically binding to cd300c antigen or receptor thereof |